DR info

臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 23

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Concerta
   University of Geneva, Switzerland
      2016   -   NCT04647500   Switzerland;
EMEA/H/C/000109
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands;
NFC-1
   Aevi Genomic Medicine
      2016   Phase 1   NCT02895906   United States;
Rilutek
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands;
Riluzole
   Academisch ziekenhuis Maastricht
      2021   Phase 3   EUCTR2021-002011-61-NL   Netherlands;
Risperdal
   University of Geneva, Switzerland
      2017   -   NCT04639960   Switzerland;
ZYN002
   Zynerba Pharmaceuticals, Inc.
      2020   Phase 1/Phase 2   NCT05149898   Australia;United States;